Spineway Valuation
Is ALSPW undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ALSPW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ALSPW's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALSPW's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALSPW?
Key metric: As ALSPW is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ALSPW's PS Ratio? | |
|---|---|
| PS Ratio | 0.007x |
| Sales | €11.36m |
| Market Cap | €75.97k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.08x |
| Enterprise Value/EBITDA | -0.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ALSPW's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1x | ||
ALICR I.CERAM | 0.2x | n/a | €173.6k |
ALPIX Pixium Vision | 0.9x | n/a | €1.5m |
ALSMA S.M.A.I.O | 1.9x | 27.6% | €12.8m |
ALBLU Bluelinea Société Anonyme | 1.2x | n/a | €11.4m |
ALSPW Spineway | 0.007x | 12.3% | €76.0k |
Price-To-Sales vs Peers: ALSPW is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (1x).
Price to Sales Ratio vs Industry
How does ALSPW's PS Ratio compare vs other companies in the FR Medical Equipment Industry?
Price-To-Sales vs Industry: ALSPW is good value based on its Price-To-Sales Ratio (0x) compared to the European Medical Equipment industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is ALSPW's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.007x |
| Fair PS Ratio | 0.04x |
Price-To-Sales vs Fair Ratio: ALSPW is good value based on its Price-To-Sales Ratio (0x) compared to the estimated Fair Price-To-Sales Ratio (0x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Equasens Société anonyme
€625.3m
Provides healthcare IT solutions in Europe.
EQS
€40.70
7D
-7.1%
1Y
-29.1%
Laboratoires Euromedis Société anonyme
€13.0m
Through its subsidiaries, designs, manufactures, and distributes medical equipment under the Euromedis brand name for healthcare professionals, local communities, and individuals in France and internationally.
ALEMG
€4.57
7D
-3.6%
1Y
-4.2%
emeis Société anonyme
€901.5m
Operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.
EMEIS
€5.21
7D
-10.7%
1Y
-98.3%